Background: The effectiveness of screening for lung cancer (LC) in smokers on a population level, as distinct from the special circumstances that may apply in a randomized trial of selected volunteers, has not been thoroughly investigated. Here we evaluate by the standardized mortality ratio (SMR) indicator the impact of a chest X-ray (CXR) screening programme carried out at community level on LC mortality in smokers. Methods: All smokers of >10 pack-years, of both genders, ages 45-75 years, resident in 50 communities of the Province of Varese, Italy, screening-eligible, in 1997 were invited by their National Health Service (NHS) general practitioner physicians to a nonrandomized programme of five annual CXR screenings. The entire invitation-to-screen cohort (n = 5815 subjects) received NHS usual care, with the addition of CXR exams in volunteer participants (21% of invitees), and was observed through December 2006. To overcome participants' selection bias of LC mortality assessment, for the entire invitation-to-screen cohort we estimated the LC-specific SMR, based on the local reference population receiving the NHS usual care. Results: Over the 8-year period 1999-2006, a total of 172 cumulative LC deaths were observed in the invitation-to-screen cohort; 210 were expected based on the reference population. Each year in the invited cohort the observed LC deaths were fewer than expected. The cumulative LC SMR was 0.82 (95%CI, 0.67-0.99; p = 0.048), suggesting that LC mortality was reduced by 18% with CXR screening. Conclusion: Implementation of a CXR screening programme at community level was associated with a significant reduction of LC mortality in smokers.
Introduction
Lung cancer (LC) is a relevant public health problem worldwide. Beyond prevention and cessation of cigarette smoking, other strategies are needed, because most who will succumb to this disease are current or former smokers [1] . No public policy organization recommends chest X-ray (CXR) screening, as randomized studies showed no LC mortality benefit [2] [3] [4] [5] [6] . However, the published randomized CXR screening trials present relevant methodological weaknesses [1, 4, 7, 8] ; moreover, these studies were performed in highly selected volunteers [2, 3, 5] , and the external value of their results remains uncertain. Notably, the U.S. Preventive Service Task Force concluded that the evidence is insufficient to recommend for or against screening with CXR [9] . The effectiveness of screening for LC in the community, as distinct from the special circumstances that may apply in a randomized trial of volunteers, has not been thoroughly investigated and remains controversial [10] . With the aim to assess whether radiographic screening of smokers in the community setting in Italy decreases LC mortality, in 1997 we started a nonrandomized observational study of CXR screening in the PREDICA cohort [11] . The latter is a clearly defined populationbased cohort of smokers of the Varese Province, hereafter referred to as "cohort", that was invited to an annual CXR screening programme and prospectively followed up. We previously reported the cohort's demographic characteristics, screening protocol, participants adherence, and LC detection results [11, 12] . After completion of the CXR screening programme, here we evaluate its effectiveness in the cohort by estimating the standardized mortality ratio (SMR), an indicator recently used by other investigators to document the significant LC mortality reduction achieved by computed tomography (CT) screening of smokers [13] .
Materials and methods

Study design
This is a prospective nonrandomized population-based cohort study of CXR screening for LC, with a comparison group consisting of the reference population of the screening catchment geographical district. The cohort, made of the totality of residents in 50 communities of the Varese Province who were screening-eligible cigarette smokers, was invited to annual CXR screening for 5 years and was observed for 9.5 years. In this geographical area no other LC screening projects were ongoing. At the end of study, we evaluated the impact of screening on LC mortality in the cohort. To this effect, as our endpoint we estimated the cumulative LC SMR, expressed as the ratio of total LC deaths observed in the entire screening-invited cohort to total LC deaths expected based on the local reference population receiving usual care. This intention-to-treat approach for analysis of the screening programme effectiveness overcomes the participants' selection bias [14, 15] .
The cohort
We aimed to recruit a population-based cohort of approximately 5000 smokers, a sample size similar to that of the intervention arm in the Kaiser Permanente trial [16] and in the Mayo Lung Project [2] . Recruitment of the cohort was effected by a pool of 50 general practitioner (GP) physicians of the Italian National Health Service (NHS), as previously described [11] . Notably, the medical practices of these GPs were located in 50 communities scattered over rural and urban areas, a large sample of the total 230 communities of the 44-town screening catchment area in the Varese Province [11] . Briefly, based on practice records, in early 1997 the GPs invited to a CXR screening programme the totality of smokers resident and registered in their community practice who possessed all the following inclusion criteria: both genders, birth cohort 1923-1953, current or ex-smoker of >10 pack-years. Exclusion criteria were: subject unfit for surgery or with diagnosed/suspected LC. After exclusion of 110 noneligible candidates, 5815 subjects featuring a median smoking history of 32.8 pack-years [interquartile range (IQR), 22.8-46 .0], constituted the population-based cohort of this study. The screening programme was offered free of charge and consisted of a baseline two-view CXR exam and an annual repeat screen for 4 years. The 1244 individuals (21% of the cohort) who accepted the invitation undertook the baseline CXR examination during a 4.5-year recruitment period (from July 1997 through December 2001, median in February 1998) and were defined as participants in screening. All participants signed an informed consent form; for nonparticipants (79% of the cohort), informed consent was waived. In addition, during 1997-2001 a total of 1221 uninvited screeningeligible individuals (resident in the 44-town catchment area, but outside the 50 communities of cohort recruitment) requested to participate after learning about the screening programme. Also these additional candidates signed informed consent, and undertook the screening protocol, but they constituted a distinct group of "uninvited participants" that will be evaluated in a separate study.
All names were encrypted, as approved by the Varese Hospital and Health District Ethics Committee. The data collected in this study were stored in a secure database at the Center for Thoracic Surgery, University of Insubria.
Standard of care, screening and follow-up of the cohort
The NHS usual care was provided to the entire cohort. In addition, participants underwent screening by chest radiographs, according to the previously described protocol [12] . The study lasted from July 1, 1997 until December 31, 2006 and during this interval the entire cohort was observed. After baseline screening, the 1244 participants underwent a total of 4337 annual repeat screens. The standard of care in Varese was used to investigate suspicious screen-detected or nonscreen-detected CXR abnormalities, without special algorithm. Management of LCs was centralized in the Varese University Hospital, and cases were treated by usual international criteria [17] regardless of mode of LC detection. At study cut off, the vital status of 98.5% of cohort individuals were ascertained by linkage with the Lombardy Health Registry of all residents in the Lombardy Region. At study cut off 85 subjects (1.5% of cohort) were untraceable. In deceased cohort subjects, death certificates were used to identify LC as the cause of death, by linkage with the Varese Province Mortality Registry, after review by the mortality review committee of this study (LD, AI, NR, FS, APo, WM), as previously described [11] . Deaths attributed to LC treatment complications were filed as deaths from LC. The LC deaths that occurred in the cohort were recorded by gender and age strata.
Lung cancer standardized mortality ratio
We excluded from LC mortality analysis the initial period of study, from July 1997 through December 1998, as we presumed that screening was unlikely to decrease LC mortality immediately. Moreover, exclusion of this initial 18-month period minimizes the healthy-cohort recruitment bias, i.e. an artificially low LC mortality in the cohort due to enrolment of asymptomatic subjects [18] . Furthermore, a preliminary joinpoint analysis [19] identified in 1999 as the year during which a statistically significant mortality trend inflexion occurred in the cohort. Accordingly, we confined the analysis of LC SMR in the cohort to the 8-year interval between January 1, 1999 and December 31, 2006. This timeframe was chosen based on the suggestion to add about 4 years after the end of active screening (median in 2002 in our study) to evaluate the effectiveness of screening using LC mortality [5] . Our analysis was not extended over a longer period, because any benefit from short-term screening is likely transient [8] . To calculate the cumulative LC SMR of the cohort during 1999-2006, the ratio's numerator (number of observed LC deaths) was available from the cohort follow-up, while the denominator (number of expected LC deaths) was calculated as follows:
(a) First, we identified the source population of the cohort alive as of January 1, 1999, constituted by all individuals of birth cohort 1923-1953 who were alive by that date and resident in all 230 communities of the 44-town catchment area [11] (Fig. 1) . This source population was searched by linkage with the Varese Province general population registry, and consisted of 122,074 persons, shown by strata in Table 1 . survey [20] (Table 2 ). In total 26,656 subjects formed the reference population. source population individuals were ascertained by deterministic record linkage with the Varese Province population registry and with the Lombardy Health Registry of all residents in the Lombardy Region [21] . At study cut off, 1.8% of subjects of the source population were untraceable. All LC deaths which occurred Table 2 Reference population by strata, estimated multiplying the source population strata ( multiplied the estimated number of LC deaths in each reference population stratum (d) by the ratio of cohort subjects alive as of January 1, 1999 to the number of reference population subjects in the stratum. The total number of LC deaths expected in the cohort was the sum of expected LC deaths in each stratum.
For the above calculations we assumed that no substantial changes occurred during 1999-2006 in the proportion of smokingattributable LC deaths and in the ratio of cohort subjects to reference population subjects.
Statistical analysis
Data are presented as frequency, percentage, mean or median, as appropriate; 95% confidence interval (CI) and IQR are shown. Differences were tested by Student's t test, chi square test, Fisher's exact test, or Mann-Whitney U test as required by type and distribution of variables.
Joinpoint regression analysis was used to identify the point where a statistically significant change in linear slope of the mortality trend over the study period occurred [19] . The joinpoint analysis was performed with software from the surveillance research programme of the U.S. NCI [24] .
The LC SMR was computed using STATA program version 11.2 (Stata Corporation, College Station, TX). Two-tailed p values of <0.05 were considered significant. Analysis was performed at the Department of Public Health and Community Medicine, University of Verona. Approval of this study and permission to access and analyze the anonymized linked data reported in this paper was granted by the Varese Hospital and Health District Ethics Committee. This study is registered, ISRCTN90639073.
Results
Over the 8-year period 1999-2006, cumulatively 172 LC deaths were observed in the cohort, while 1405 LC deaths altogether were recorded in the source population (Table 3) .
The LC deaths estimated in the reference population strata, and those expected in the cohort are shown in Table 3 . In total 210 LC deaths were expected in the cohort. Each year during 1999-2006 the number of LC deaths observed in the cohort was lower than that expected based on the reference population (Fig. 2) . During 1999-2006, the cumulative LC SMR was 172/210 = 0.82 (95%CI, 0.67-0.99; p = 0.048). This result indicates that the risk of LC death for the smokers invited to the screening programme at community level was reduced by 18% compared to that of the reference population smokers receiving usual care. The numbers of observed and expected LC deaths by age in the cohort are given in Table 4 . Age, years Men, n Women, n Total, n
45 -49  43  37  8  19  16  3  62  53  11  50-54  85  73  15  39  34  4  124  107  19  55-59  127  109  24  57  49  6  184  158  30  60-64  185  159  34  75  65  7  260  224  41  65-69  275  237  42  92  79  9  367  316  51  70-74  252  217  42  87  75  8  339  292  50  75-79  48  41  7  21  18  1  69  59  8   Total  1015  873  172  390  335  38  1405  1208  210 Note. Lung cancer deaths: (A) observed in the source population; (B) estimated in the reference population; (C) expected in the cohort. (B) was estimated multiplying (A) by 0.86 (proportion of smoking-attributable LC deaths). (C) was estimated multiplying (B) by the ratio of cohort subjects to reference population subjects in the stratum. LC, lung cancer.
Fig. 2.
Cumulative lung cancer deaths observed in the screening-invited cohort ( ), and expected based on reference population receiving usual care ( ).
Discussion
In this study we assessed the LC SMR in a well defined population-based cohort of smokers invited to a CXR screening programme at community level. After screening implementation we found that LC mortality over an 8-year period was significantly reduced in the entire invitation-to-screen cohort of smokers. In contrast, no substantial LC mortality benefit from screening with chest radiographs was shown in the PLCO cancer randomized trial after 13 years of follow-up [5] . These opposite results do not surprise, as the subjects targeted for screening in our study were quite different from those of the PLCO. While we investigated the totality of screening-eligible ever-smokers resident in 50 communities of the Varese Province, characterized by high LC incidence (5.15/1000 person-years) [11] , the PLCO trial was not specifically designed to investigate smokers [25] and recruited highly selected volunteers, as reflected by the fact that enrolment averaged approximately 1% of the invited population [26] . Moreover, in the PLCO about 80% of the total of intervention group LCs were nonscreen-detected and could be diluting any screening effect [5] . While in theory a population-based randomized trial is the ideal method to assess the efficacy of an LC screening intervention [27] , in practice the historical randomized CXR screening trials have subsequently been associated with important methodological weaknesses [1, 4, 7, 8] . In addition, the recently reported findings of the PLCO randomized radiographic screening are difficult to generalize to smokers, as about half of participants were never smokers [5] . Observational studies of CXR screening in all eligible smokers of the population, with appropriate comparator groups, may contribute important information with regard to the effectiveness of screening in the community setting. In our observational study, 21% of the invited population-based cohort chose to participate in screening. This attendance rate is similar to the 20-33% participation recorded in Japanese mass screenings with CXR [28, 29] , and indicates a generally limited response to LC screening invitation. Because the assessment of screening efficacy may be biased by selection of participants [11] , in our study we evaluated the overall impact of screening on LC mortality in all the invitees. The assessment of SMR according to invitation-to-screen has been previously used for the evaluation of population-based cancer screening, in order to eliminate self-selection bias of participants [14, 15] . Other investigators, using the SMR to compare the LC mortality experience in a CT screened cohort of smokers in New York State and in two large unscreened cohorts, reported significant reductions in deaths from LC, documented by SMR respectively of 0.64 and 0.36 [13] . In our study the cumulative LC SMR of the CXR screening invited cohort was 0.82, a result that must be interpreted cautiously. Because the design of our study was observational, we assumed that the cohort and the reference population were identical in all important variables except the intervention, or that we could correct for the relevant differences. The LC SMR may reflect the effectiveness of our screening programme only if the LC mortality risk profile in the cohort and in the reference population were identical at baseline, and if the two groups received the same standard of care except for screening in the cohort. As to comparability, it is noteworthy that the cohort and the reference population were contemporary and were extracted by the same smoking history criteria (Table 2 ) from the Varese Province general population of both genders, of birth cohort 1923-1953, resident in the 44-town catchment area [11] . Under these circumstances, it is highly unlikely that our observational study was vulnerable to confounding by important differences between the cohort and the reference population, except for confounding caused by the absence of subjects unfit for surgery or with LC symptoms in the cohort at baseline. To correct for this healthier-cohort bias that is in favour of screening effectiveness, we excluded from LC mortality analysis the initial 18 months of study, as suggested by other authors [18] . Because the time from LC symptoms to death is rarely longer than a few months, the healthier-cohort bias of the cumulative LC SMR assessed during the subsequent period 1999-2006 was likely negligible. As to the completeness of follow-up and of LC deaths data collection, it must be noted that the vital status ascertainment rates at study cut off were very high, and nearly identical in the cohort and in the source population (98.5% and 98.2%, respectively). Notably, contamination by CXR screening that was performed in approximately 9% of the reference population (1244 participants of the cohort and 1221
